Nonprotective role of losartan in cisplatin-induced nephrotoxicity in ovariectomized rat model treated with estradiol

Journal of Pharmaceutical Negative Results

Volumn 6, Issue 1, 2015, Pages 2-6

  Ghadirian, Fereshteh ^a,b   Nematbakhsh, Mehdi ^a,c   Roozbehani, Shahla ^b   Mazaheri, Safoora ^a   Talebi, Ardeshir ^a   Pezeshki, Zahra ^a   Ashrafi, Farzaneh ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c Isfahan MN Institute of Basic and Applied Sciences Research   (Iran)

Author keywords

Cisplatin; Estrogen; Losartan; Nephrotoxicity; Ovariectomized rats

Indexed keywords

CISPLATIN; CREATININE; ESTRADIOL VALERATE; LOSARTAN; MALONALDEHYDE; NITRITE; SESAME SEED OIL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; KIDNEY MASS; KIDNEY PARENCHYMA; NEPHROTOXICITY; NONHUMAN; OVARIECTOMY; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

EID: 84946548416     PISSN: 09769234     EISSN: 22297723     Source Type: Journal    
DOI: 10.4103/0976-9234.157375     Document Type: Article

References (23)

1. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci 2007;334:115-24.
2. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
3. Haghighi M, Nematbakhsh M, Talebi A, Nasri H, AshrafiF, Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: Gender-related differences. Ren Fail 2012;34:1046-51.
4. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: A review of toxicities and therapeutic applications. Vet Comp Oncol 2008;6:1-18.
5. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996;50:1026-31.
6. Kuhlmann MK, Burkhardt G, Köhler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997;12:2478-80.
7. Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, Nasri H, Talebi A, Safari T, et al. Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 2013;7:383-9.
8. Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, AshrafiF, Nasri H, Talebi A, et al. Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol 2012;2012:284896.
9. Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR. The role of the renin-Angiotensin system in cisplatin nephrotoxicity. Ren Fail 1995;17:665-74.
10. Beleh MA, Lin YC, Brueggemeier RW. Estrogen metabolism in microsomal, cell, and tissue preparations of kidney and liver from Syrian hamsters. J Steroid Biochem Mol Biol 1995;52:479-89.
11. Pezeshki Z, Nematbakhsh M, Nasri H, Talebi A, Pilehvarian AA, Safari T, et al. Evidence against protective role of sex hormone estrogen in cisplatin-induced nephrotoxicity in ovarectomized rat model. Toxicol Int 2013;20:43-7.
12. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 2010;1:87-93.
13. Mazaheri S, Nematbakhsh M, Bahadorani M, Pezeshki Z, Talebi A, Ghannadi AR, et al. Effects of fennel essential oil on cisplatin-induced nephrotoxicity in ovariectomized rats. Toxicol Int 2013;20:138-45.
14. Jilanchi S, Nematbakhsh M, Bahadorani M, Talebi A, Eshraghi-Jazi F, Mansouri A, et al. Vitamin e is a nephroprotectant agent in male but not in female in a model of cisplatin-induced nephrotoxicity. ISRN Nephrol 2013;2013:280395.
15. Endo Y, Kanbayashi H. Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of cisplatin. Pharmacol Toxicol 2003;92:300-3.
16. Nematbakhsh M, AshrafiF, Nasri H, Talebi A, Pezeshki Z, Eshraghi F, et al. A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats. J Res Med Sci 2013;18:370-3.
17. Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A, AshrafiF. Gender difference in cisplatin-induced nephrotoxicity in a rat model: Greater intensity of damage in male than female. Nephrourol Mon 2013;5:818-21.
18. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009;55:399-406.
19. AshrafiF, Nematbakhsh M, Safari T, Talebi A, Nasri H, Khazaei M, et al. A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis 2012;6:361-5.
20. Branham WS, Zehr DR, Sheehan DM. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc Soc Exp Biol Med 1993;203:297-303.
21. Rastghalam R, Nematbakhsh M, Bahadorani M, Eshraghi-Jazi F, Talebi A, Moeini M, et al. Angiotensin type-1 receptor blockade may not protect kidney against cisplatin-induced nephrotoxicity in rats. ISRN Nephrol 2014;2014:479645.
22. Miura T, Muraoka S, Ogiso T. Inhibition of lipid peroxidation by estradiol and 2-hydroxyestradiol. Steroids 1996;61:379-83.
23. de Bairros AV, Roehrs M, Ribeiro G, de Freitas F, Moreira AP, Tonello R, et al. Treatment with N-Acetylcysteine does not alter blood glucose levels and the oxidative stress status in diabetic rats. J Pharm Negat Results 2013;4:5-12.